HC Andersen Capital Events 08/02: Meet the top management in Zerion Pharma & Inderes

HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.

Zerion Pharma - Company Introduction
Meet Zerion Pharma’s management team – CEO Ole Wiborg and CFO Jakob Dynnes Hansen when they introduce the company in relation to a private placement of 2-3 mio. EUR. Zerion Pharma is a non-listed Danish company.  

The company aims to make a real difference in health care with its Dispersome™ technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market, and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome® technology makes it possible to reduce the number of active drugs by up to 75%.  

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Claus Thestrup 1.51 PM 02/02-2023. 

Sign up via. link

Wednesday 8th of February 11:00 - 11:30


Inderes - Presentation of year-end-report 2022
On the 7th of February, Inderes reported its Q4 2022 and annual report for 2022. For the full year 2022, revenue grew to EUR 13.5m (EUR 11.8m in 2021), and EBITA declined to EUR 1.3m (EUR 2.3m in 2021). Looking into 2023, Inderes now guides revenue above EUR 17m, particularly driven by growth from its Swedish acquisitions of Streamfabriken and Financial Hearings. In 2023, Inderes also expects to improve its EBITA margin from the 2022 level of 9.4%.

Inderes’ CEO Mikael Rautanen will present the results on the 8th of February at 13:30 (CET) in a virtual live event followed by a Q&A session.

Disclaimer HC Andersen Capital receives payment from Inderes for a Digital IR/Corporate Visibility subscription agreement. Inderes and HC Andersen Capital are strategic partners, and Inderes holds 20% ownership in HC Andersen Capital. A number of HC Andersen Capital employees own shares in Inderes. /Kasper Lihn 14:30, 7 February 2023.

Wednesday 8th of February 13:30 - 14:00

Sign up via. link


Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations.

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.